Background: Prostate cancer (PCa) is a leading cause of cancer morbidity and mortality in men worldwide; however, PCa incidence and mortality rates vary widely across geographic regions and ethnic groups. The current study was designed to elucidate the pivotal factors involved in PCa occurrence and development.
| INTRODUCTION
Prostate cancer (PCa) is the most common malignancy in men and the second leading cause of cancer-related death in Western countries. 1 PCa incidence and mortality rates vary widely across geographic regions and ethnic groups. In particular, Asian populations have a substantially lower incidence of PCa than Caucasians or African-Americans, suggesting a genetic contribution to PCa susceptibility. [2] [3] [4] The genetic etiology and pathogenesis of PCa remain unclear.
Advances in genomic technology over the last two decades have revealed some clues. The androgen/androgen receptor (AR) signaling pathway plays a central role in PCa development and progression, and PCa growth is usually androgen-dependent. Changes in ARrelated genes can increase the risk of PCa. 5 TMPRSS2-ERG fusion, which rearranges two genes-the androgen-regulated gene TMPRSS2 and the E26 transformation-specific (ETS) transcription factor ERGis discovered quite specific in PCa. 6 PTEN loss or point mutation is frequently observed in advanced PCa. Heterozygous loss of NKX3.1 occurs in PCa and this gene functions as a tumor suppressor. 7, 8 However, precise causal lesions have yet to be identified. The paucity of published data is particularly acute in China, where the aging population presents an increasingly heavy medical burden. 9 We therefore designed a study of patients with PCa from China to identify characteristic molecular lesions associated with PCa pathogenesis and development that may have potential clinical application.
We conducted RNA sequencing (RNA-seq) and analyzed genomewide expression data from tumor and adjacent normal tissues from Chinese PCa patients. We subsequently found that TWIST2 showed strikingly reduced expression in tumor tissues and confirmed this finding by quantitative reverse-transcription polymerase chain reaction (RT-qPCR) in an additional cohort of paired tumor and normal tissues. Low basal expression levels of TWIST2 were accompanied by hypermethylation of CpG islands. In accordance with these findings, immunohistochemical staining showed lower expression of the TWIST2 protein in PCa tissues than in normal and prostatic intraepithelial neoplasia (PIN) tissues.
TWIST2, a basic helix-loop-helix transcription factor, plays a crucial regulatory role in the progression of bone development, tumorigenesis, tumor progression, and epithelial-mesenchymal transition (EMT). TWIST2 has a dual role in tumorigenesis. This protein is highly expressed in a variety of human tumors, playing an oncogenic role, while its expression is decreased in some tumors, indicating a tumor-suppressive role. A high level of TWIST2 messenger RNA (mRNA) was found in melanoma, renal cancer, and esophageal squamous cell carcinoma tissues and corresponding cell lines. 10 However, no expression was observed in lung cancer, 10,11 and significantly decreased expression was observed in osteosarcoma, with the expression level negatively correlated with tumorigenesis.
TWIST2 is selectively silenced in chronic lymphocytic leukemia, 12 and is epigenetically inactivated in acute lymphoblastic leukemia. 13 There are few reports on the functions of TWIST2 in PCa.
When we overexpressed TWIST2 in LNCap cells, cell proliferation and colony formation in vitro were reduced, and tumor formation in vivo in nude mice was inhibited. We performed whole genome microarray analysis of dysregulated genes in LNCap-TWIST2, LNCapvector, and LNCap cells. Some important genes involved in proliferation were regulated by TWIST2, including the androgen receptor (AR), cyclins, transcription factors, homeobox genes, forkhead box genes, SNAI2, and SOX2.
Our results suggest that the TWIST2 gene could be a key tumor suppressor involved in the pathogenesis of PCa by influencing the regulation of its downstream genes. Epigenetic modification of the TWIST2 gene in prostate tumors may be an underlying mechanism for its decreased expression. All cases were histologically confirmed PCa. Prostate samples were obtained from patients undergoing radical prostatectomy at one of the two hospitals. After negative surgical margin was achieved, adjacent normal tissue was collected from the prostate. All tissues were snap frozen in liquid nitrogen for storage. Samples were evaluated by frozen sectioning with a fresh blade and preparation of hematoxylin-eosin slides. A pathologist confirmed the presence or absence of tumor tissue in the slides for each sample. For tumor sections, the presentation of the overall tumor composition was also assessed, with samples exhibiting greater than 70% neoplastic cells considered optimal for subsequent RNA-seq analysis.
| MATERIALS AND METHODS

| Collection and processing of tissues
Clinical data, including age at diagnosis, Gleason score, tumor stage, and serum prostate specific antigen (PSA) levels, were obtained by a review of medical records. Patients with PSA more than 20 ng/mL, Gleason score ≥8, and/or pathological stage III or higher classification were defined as having aggressive PCa.
| RNA extraction
Total RNA was extracted with TRIzol (Ambion) reagent. Extracted RNA was quantified using a NanoDrop 2000 (Thermo Fisher Scientific) and 1% agarose gel electrophoresis.
| RNA sequencing and data analysis
RNA-seq libraries were constructed and sequenced on the Illumina HiSeq. 2000 sequencing platform (BGI, Shenzhen, China) as previously described by Laborde et al. 6 A whole transcriptome analysis approach was applied to assess the gene expression of all known genes. Raw sequencing reads from tumor and adjacent normal tissues were aligned to the human genome reference build 38 using the Geospiza GeneSifter Analysis Edition pipeline as previously described. 14 
From
the aligned data, expression values for annotated genes were calculated by adding the number of reads mapping to all exons and dividing that value by the total number of mapped million reads per sample (reads per kilo bases per million mapped reads, RPKM). We calculated the fold changes in the RPKM values for all genes between each tumor and its matched normal sample to select genes with expression alterations of greater than two-fold or less than 0.5-fold.
| Quantitative reverse-transcription polymerase chain reaction analysis
Total RNA from each sample was primed with oligo-dT and reversetranscribed with complementary DNA (cDNA) synthesis kits (Promega, Madison, WI). Then, cDNA was used as the template for RT-qPCR (SYBR Green; Takara, Dalian, China), which was performed using an iQ5 system (Bio-Rad) according to the manufacturer's instructions. The ΔC t values were calculated using GAPDH as the internal control, and the ΔΔC t values were calculated by comparing the ΔC t in the tumors with the ΔC t in their matched normal control tissues. Primers were designed within the last exon of each gene, relatively close to the 3′ end. The PCR primer sequences used are shown in Table S1 .
| Nested bisulfite-specific PCR and genomic sequencing of bisulfite-modified DNA
Genomic DNA was purified from lysed tissues with phenolchloroform extraction and precipitated with isopropanol. Two micrograms of DNA was modified by sodium bisulfite and purified with an EpiTect Bisulfite kit (Qiagen, Shanghai, China). Genomic sequencing analysis of CpG islands in the genes of interest in the tumor and adjacent normal tissues was performed by nested methylation-specific PCR. Primers were created for each gene using Meth Primer Express Software v1.0. All primer sequences are listed in Table S2 . For the steps, refer to the supporting information.
| Immunohistochemistry
Prostate tissues were fixed in formalin and embedded in paraffin.
First, 6 × 8 tissue blocks were created, and 4-μm thick tissue sections were then cut and placed on glass slides. After blocking, slides were incubated at 4°C in a humidified chamber overnight with a monoclonal anti-TWIST2 antibody (cat# WHO11758M1;
Sigma-Aldrich, Shanghai, China) at a 1:500 dilution. A biotinylated secondary antibody and horseradish peroxidase-labeled avidin were subsequently applied. The diaminobenzidine method was used for visualization. Expression levels of proteins in the PCa and adjacent normal tissue sections were scored according to the staining pattern. The intensity of staining was designated as absent (0) or present (1+, 2+, or 3+) by two independent investigators who were blinded to the tissue type. When the nucleus was also stained, 1 point was added to the score. 15 
| Western blot analysis
Western blot analysis was performed as described previously. 18 Cell lysates were subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and immunoblot analysis with antibodies against TWIST2, FLAG, and GAPDH (Sigma Aldrich, Shanghai, China). 
| Cell proliferation assay
| Colony formation assay
Soft agar at a concentration of 0.5% and 0.25% was used as the base and upper layers, respectively. One thousand cells ZHAO ET AL.
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were seeded in 60-mm dishes and maintained in complete medium for 28 days. After most of the colonies had expanded to more than 50 cells, the dishes were imaged, and the colonies were counted. At least three independent replicates were used in each assay. Table S3 shows the demographic characteristics of the participants in this study. The cases used for RNA-seq (case group 1) and for validation (case group 2) had a similar mean patient age and tumor aggressiveness. Missing data were not included when proportions were calculated.
| Tumor growth assay
| RESULTS
| Baseline clinical characteristics
| RNA-seq reveals that a selected group of genes is aberrantly expressed in prostate cancer samples
To gain an insight into the molecular pathogenesis of prostate cancer in the Chinese population, we assessed samples for genetic alterations using RNA-seq in 10 prostate cancer samples and their matched, adjacent normal tissues.
Overall, we selected 21 downregulated and 21 upregulated potential candidate genes that were significantly differentially expressed and with a greater than two-fold change within the 10 tumor and normal tissue pairs; 22 of these genes had at least one report related to PCa, but the other 20 genes were previously unreported as being related to PCa ( Figure 1A and Table S4 ).
The downregulated genes in the 10 prostate tumors included known drivers of prostate carcinogenesis, such as TP63 and CDKN1A;
the PCa-specific gene MSMB; and genes previously reported as abnormally regulated in PCa, such as WNT2, WIF1, and S100A2. We also found downregulated genes that had not been previously reported to be associated with PCa but that had been related to benign prostatic hyperplasia, including NELL2 20 and GSTM5, 21 sugsuggesting that these genes might play a role in the early stages of tumorigenesis in the prostate. The expression of several genes that are well established in other cancers, such as SCGB3A1 (an excellent marker for early detection of breast cancer) 22 and NRSN2 (a candidate biomarker for hepatocellular carcinoma, HCC), 23 was also significantly decreased.
| The expression of nine genes was confirmed in additional PCa samples
Of these 42 genes, 10 with decreased expression (TWIST2, WNT2, WIF1, NELL2, ID4, GSTM5, NRSN2, CDKN1A, SCGB3A1, and S100A2) and five with increased expression (ACSM1, BANK1, SFTPA2, TFF3, and GAL; with fold changes ranging from 2.26 to 93.91) were present in more than 50% of tumors ( Figure 1A , Table S4 ). Figure 2A ). The mRNA levels of TWIST2 were associated with the previously unreported tumor-related genes WNT2 and NELL2, as well as with the previously reported WIF1 (Table S5 ). 
| Decreased TWIST2 protein expression in human prostate tumors
| The TWIST2 gene promoter is hypermethylated in PCa specimens
Analysis of the genomic architecture of TWIST2 showed a dense CpG island ( Figure S1 ). Thus, we first characterized the methylation status of CpG dinucleotides within the TWIST2 promoter in 18 tumor and normal tissue pairs. Bisulfite-specific PCR and Sanger sequencing revealed higher methylation of the TWIST2 promoter in tumor tissues than in adjacent normal tissues (Figure 3) . The methylation status of eight CpG sites (+108, +111, +118, +137, +143, +151, +175, and +183) was significantly correlated with the TWIST2 mRNA levels (all P < .05; Table S6 ). These data indicate that TWIST2 promoter methylation might account for the downregulation of gene expression.
| Overexpression of TWIST2 inhibits LNCap cell proliferation and colony formation in vitro
We examined the expression of TWIST2 in four cell lines: LNCap, VCap, PC3, and RWPE-1. We found that TWIST2 expression was To assess the effect of TWIST2 on the tumorigenic ability, we overexpressed TWIST2 in LNCap cells, which exhibited decreased protein expression, by gene transfer. We then determined the effect of TWIST2 on the growth of PCa cells in vitro and in vivo.
Overexpression of TWIST2 in LNCap cells ( Figure 4A ) decreased their proliferation ( Figure 4B ). TWIST2-expressing LNCap cells formed fewer and smaller colonies than vector cells in 60 mm dishes after 28 days of incubation ( Figure 4C-F) . These data suggest that TWIST2 inhibits the growth of PCa tumor cells.
| Overexpression of TWIST2 attenuates tumorigenic potential in vivo
LNCap cells were implanted subcutaneously into BALB/c nude mice, and overexpression of TWIST2 resulted in marked inhibition of tumor growth ( Figure 4G-K) . Collectively, our results indicate that Figure S4 ).
We examined the RSEM levels of TWIST2 and these 63 selected genes from the TCGA Prad provisional database and the Z-score from the TCGA Prad mkscc database in 61 PCa pathological tissues and calculated their Spearman correlations with TWIST2. The results from these two databases were quite consistent. We found that most selected genes were positively or negatively correlated with TWIST2.
The relationships of 43 of 53 genes from the TCGA Prad provisional database and 44 of 47 from the TCGA Prad mkscc database were the same as those observed in our GeneChip results.
| DISCUSSION
Following a series of investigations on samples from Chinese PCa patients, we present the first reported evidence that the TWIST2 gene could be a key tumor suppressor involved in the occurrence of PCa.
TWIST2 has previously been implicated in the pathogenesis of a range of cancers. Its role in the initiation and metastasis of various solid tumors is well established, and a tumor-suppressor function in murine osteosarcoma cells and human acute myeloid leukemia (AML) has recently been reported. 24, 25 The involvement F I G U R E 4 TWIST2 inhibits LNCap cell proliferation and colony formation in vitro, and growth of LNCap tumors in vivo. A, Western blot analysis of FLAG, TWIST2, and GAPDH. B, Cell counting kit-8 assays of the cell proliferation of LNCap, LNCap-vector, and LNCap-TWIST2 cells. C, Number of colonies formed by the three cell lines. D-F, Colony formation assay of LNCap, LNCap-vector, and LNCap-TWIST2 cells. G, I, Ten male BALB/c nude mice aged 6 to 8 weeks were randomly divided into two groups. Vector-or TWIST2-expressing LNCap cells (1 × 10 6 ) were subcutaneously injected into the BALB/c nude mice. H, J, Solid tumors isolated from each mouse subcutaneously injected with vector-or TWIST2-expressing LNCap cells. K, Growth of tumors derived from nude mice 14 days after injection. Student t test (two-sided) was used to determine significance. The data are shown as the mean ± SD (*P < .05) [Color figure can be viewed at wileyonlinelibrary.com] of TWIST2 in both osteosarcoma and PCa suggests at a potential role in bone metastasis. 26 TWIST2 showed evidence of disease-specific methylation in our patients. Aberrant DNA methylation, which leads to inappropriate gene expression, has been extensively investigated in PCa, and it is believed to play an important role in the initiation and development of this disease. Tumor suppressor genes reported to be hypermethylated in PCa include WIF1, 27 PCDH10, 28 and ID4. 29 In addition to TWIST2, four other genes exhibited highly frequent downregulation in our PCa samples, namely, WNT2, WIF1, NELL2, and ID4. Wnt signaling plays a central role in osteoblast development and bone formation. 30 Wnts directly stimulate tumor cell growth and survival via autocrine regulation in several types of human cancer, including PCa. 31 In PCa, the roles of androgen and AR have been well described.
AR signaling plays a decisive role in regulating the growth and differentiation of both normal and cancerous prostate cells by triggering the regulation of target genes. 32 AR and some well-known AR target genes (KLK2, KLK3, KLK4, and TMPRSS2), as well as PMEPA1 (an androgen induced prostate transmembrane protein), were downregulated by overexpression of TWIST2. Clusters of cyclin-dependent kinases (CDKs) and CDK inhibitors in cell-cycle progression, forkhead box (FOX), homeobox (HOX), and ID genes were all also regulated by TWIST2. These genes co-operate to regulate the proliferation of PCa cells.
| CONCLUSIONS
In summary, our analysis of the mRNA and protein levels of selected genes in clinical specimens of human PCa revealed that TWIST2 expression is frequently downregulated in this cancer and that hypermethylation of the TWIST2 promoter may account for this decrease. Therefore, TWIST2 warrants further investigation as a possible tumor suppressor in PCa pathogenesis with potential clinical application. 
